NCT02048358View on ClinicalTrials.gov

Safety, Pharmacokinetics and Pharmacodynamics Study With 2B3-201 in Healthy Subjects and Multiple Sclerosis(MS) Patients

PHASE1TerminatedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

January 31, 2015

Study Completion Date

February 28, 2015

Conditions
Healthy VolunteersMultiple Sclerosis
Interventions
DRUG

2B3-201

DRUG

Placebo

DRUG

Methylprednisolone hemisuccinate

Trial Locations (2)

1081 HV

VUmc, PET and neurology clinical research unit, Amsterdam

2333 CH

Centre for Human Drug Research (CHDR), Leiden

Sponsors
All Listed Sponsors
lead

BBB-Therapeutics B.V.

INDUSTRY

NCT02048358 - Safety, Pharmacokinetics and Pharmacodynamics Study With 2B3-201 in Healthy Subjects and Multiple Sclerosis(MS) Patients | Biotech Hunter | Biotech Hunter